Abstract:Ras proteins are small GTPases, cycling between inactive GDP-bound and active GTP-bound states. Through these switches they regulate signaling that controls cell growth and proliferation. Activating Ras mutations are associated with approximately 30% of human cancers, which are frequently resistant to standard therapies. Over the past few years, structural biology and in silico drug design, coupled with improved screening technology, led to a handful of promising inhibitors, raising the possibility of drugging Ras proteins. At the same time, the invariable emergence of drug resistance argues for the critical importance of additionally honing in on signaling pathways which are likely to be involved. Here we overview current advances in Ras structural knowledge, including the conformational dynamic of full-length Ras in solution and at the membrane, therapeutic inhibition of Ras activity by targeting its active site, allosteric sites, and Ras-effector protein-protein interfaces, Ras dimers, the K-Ras4B/calmodulin/PI3K alpha trimer, and targeting Ras with siRNA. To mitigate drug resistance, we propose signaling pathways that can be co-targeted along with Ras and explain why. These include pathways leading to the expression (or activation) of YAP1 and c-Myc. We postulate that these and Ras signaling pathways, MAPK/ERK and PI3K/Akt/mTOR, act independently and in corresponding ways in cell cycle control. The structural data are instrumental in the discovery and development of Ras inhibitors for treating RAS-driven cancers. Together with the signaling blueprints through which drug resistance can evolve, this review provides a comprehensive and innovative master plan for tackling mutant Ras proteins.

Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?

The Roles of GTPase-activating Proteins in Regulated Cell Death and Tumor Immunity

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

Advances in the Development of Rho GTPase Inhibitors

Targeting RAS Phosphorylation in Cancer Therapy: Mechanisms and Modulators

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

RAL GTPases: Biology and Potential As Therapeutic Targets in Cancer

The Mechanisms Of Diras Family Members In Role Of Tumor Suppressor

Kras Mutation in Tumorigenesis and Cancer Therapy

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Progress in Ras Gene and Relationship Between Abnormality of Ras Regulation and Tumor

GPRC5A: an Emerging Biomarker in Human Cancer

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

The Advancement of Pathway on G Protein-coupled Receptors(GPCRs) Target to Cancer

Ran GTPase: A Key Player in Tumor Progression and Metastasis

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Targeting Rabs As a Novel Therapeutic Strategy for Cancer Therapy.

Post-translational modification of KRAS: potential targets for cancer therapy

Function and regulation of Rab GTPases in cancers

Peptide Inhibitors Targeting Ras and Ras-associated Protein–protein Interactions

Rab GTPases: Central Coordinators of Membrane Trafficking in Cancer